Acadia Pharmaceuticals (ACAD) Stock: Buy, Sell, or Hold?
ACAD - Acadia Pharmaceuticals Inc.
$19.89
-0.26 (-1.29%)
▼
5d:
-10.32%
30d:
-31.15%
90d:
-23.41%
HOLD
MODERATE Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 18, 2026 at $26.94 · last confirmed Sep 28, 2026
Strength: 8.4/10
Get Alerted When ACAD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: ACAD shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$43.26
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$26.86
25.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ACAD is currently trading at $19.89, which is considered oversold relative to its 30-day fair value range of $23.21 to $29.70. From a valuation perspective, the stock is trading at a discount (Forward PE: 22.4) compared to its historical average (28.2). Remarkably, the market is currently pricing in an annual earnings decline of 7.4% over the next few years. This pessimistic expectation contrasts with the company's recent 13.3% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is currently testing key support at $19.59. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $32.16 (+61.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACAD is in a strong uptrend. The price is currently testing key support at $19.59. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $32.16 (+61.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$23.21 -
$29.70
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
Protect Your Profits
Holding ACAD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 61.7% below Wall St target ($32.16)
- NEUTRAL: Bottoming setup forming (45/100) — watch for confirmation
- CAUTION: 5-day price weakness (-10.3%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$23.21 -
$29.70
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$19.59
Resistance Level
$27.48
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
22.39
Wall Street Target
$32.16
(+61.7%)
Revenue Growth (YoY)
16.4%
Earnings Growth (YoY)
13.3%
Profit Margin
33.4%
Valuation Discount vs History
-7.4% cheaper
PE vs Historical
22.4 vs 28.2
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.4%
(market-implied from PE analysis)
1-Year Target
$18.42
(-7%)
2-Year Target
$17.06
(-14%)
3-Year Target
$15.79
(-21%)
3-Yr Target (if PE normalizes)
(PE: 22→28)
$19.89
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 48.3%)
$64.81
(+226%)
Base:
(SPY PE: 20.4, Growth: 48.3%)
$59.06
(+197%)
Bear:
(PE: 17.3, Growth: 48.3%)
$50.20
(+152%)
📈
Valuation based on Current Earnings
Trailing PE: 9.23 | Current EPS (TTM): $2.19
Bull Case
$11.12
(-45%)
Analyst growth -50.0%, PE expands to 10.2
Base Case
$10.11
(-50%)
Market implied -50.0%, PE stable at 9.2
Bear Case
$13.75
(-32%)
Severe decline -20.0%, PE contracts to 7.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 22.4 to 28.2
Stabilization Target:
$25.06
(+26.0%)
PE Expansion Potential:
+26.0%
Share & Embed Analysis
Last updated: October 01, 2026 5:01 PM ET
Data refreshes hourly during market hours. Next update: 6:01 PM
Data refreshes hourly during market hours. Next update: 6:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACAD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
James Kihara
SELL
1030 shares
2026-04-07
Mark C Schneyer
SELL
2709 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 59 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 73 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 61 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 44 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
Advanced ACAD Option Strategies
Professional options setups generated by AI based on today's ACAD price and gamma walls.
